Results 41 to 50 of about 1,506 (115)

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

Frontiers in Pharmacology
AimsThe objective of this study is to compare the adverse events (AEs) associated with pralsetinib and selpercatinib.MethodsTo evaluate the imbalance of AEs linked to pralsetinib and selpercatinib in real-world data, the reporting odds ratio (ROR) was ...
Qiong Jie, Yuanyuan Li, Li Jing, Jinjin Chen, Yang Li   +4 more
doaj   +1 more source

Molecular Testing and Treatment Strategies in RET-Rearranged NSCLC Patients: Stay on Target to Look Forward

Journal of Molecular Pathology, 2022
RET alterations are recognized as key oncogenic drivers in different cancer types, including non-small cell lung cancer (NSCLC). Multikinase inhibitors (MKIs) with anti-RET activities resulted in variable efficacy with significant toxicities because of ...
Maria Lucia Reale, Valentina Bertaglia, Angela Listì, Silvia Novello, Francesco Passiglia   +4 more
doaj   +1 more source

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 554-567, September 2026.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source

A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review

Frontiers in Medicine
Selective rearranged during transfection (RET) tyrosine kinase inhibitor, pralsetinib, demonstrated clinical efficacy and was well tolerated in lung and thyroid cancers with RET gene mutations or fusions in clinical trials.
François Poumeaud, Marion Jaffrelot, Carlos Gomez-Roca, Iphigénie Korakis, Giulia Leonardi, Marine Joly, Julien Mazières, Rosine Guimbaud, Nadim Fares, Nadim Fares, Emily Alouani, Emily Alouani   +11 more
doaj   +1 more source

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Frontiers in Oncology, 2022
During the last two decades, kinase inhibitors have become the major drug class for targeted cancer therapy. Although the number of approved kinase inhibitors increases rapidly, comprehensive in vitro profiling and comparison of inhibitor activities is ...
Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Martine B. W. Prinsen, Yvonne Grobben, Tessa J. J. de Bitter, Antoon M. van Doornmalen, Janneke J. T. M. Melis, Joost C. M. Uitdehaag, Yugo Narumi, Yusuke Kawase, Jeroen A. D. M. de Roos, Nicole Willemsen-Seegers, Guido J. R. Zaman   +13 more
doaj   +1 more source

Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science

The Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.
Abstract Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for ...
Ya‐Feng Wen, Xiaoning Wang, Sarandeep Boyanapalli, Lee Anderson, Thao Dang, Guan Xing, Marianna Calvet, Tiffany Hart, Sreeneeranj Kasichayanula, Xiaochen Zhao   +9 more
wiley   +1 more source

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero, Niall Prendiville, Tatiana Cazorla, Maria Baena‐Nuevo, Röhm Sandra, Emilio Camafeita, Stefan Knapp, Patricia Alfonso   +7 more
wiley   +1 more source

Update on International Medical Taxonomies of Biomarkers and Their Applications in Management of Thyroid Cancers

Diagnostics, 2022
Biomarkers (BMs) are medical signs which can be precisely measured and reproduced. Mainly, BMs provide information on the likely disease which can occur in an individual. On the other hand, BMs also signal disease recurrence in patients receiving therapy.
Maria Trovato
doaj   +1 more source

Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib

CPT: Pharmacometrics & Systems Pharmacology
Pralsetinib, a potent and selective inhibitor of oncogenic RET fusion and RET mutant proteins, is a substrate of the drug metabolizing enzyme CYP3A4 and a substrate of the efflux transporter P‐gp based on in vitro data.
Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen   +7 more
doaj   +1 more source

Molecular Diagnostics in Thyroid Nodules: Current Applications, Clinical Value, and Future Perspective

Med Research, Volume 2, Issue 2, Page 204-213, June 2026.
ABSTRACT Molecular diagnostics have become an important adjunct to ultrasonography and fine‐needle aspiration (FNA) for thyroid nodules, especially in Bethesda III/IV cytology where malignancy risk is uncertain. This narrative review summarizes the diagnostic and prognostic value of key genomic drivers (BRAF V600E, RAS, RET, TERT, and selected fusions)
Guohui Xiao, Min Ding, Zhixue Min, Yihan Dong, Xuanye Cao, Qiang Lu, Cong Chen, Yahui Wu, Xin Guo, Zhen Wu, Jing Xie, Dan Xu, Haizhen Chen, Rongli Xie, Jian Fei   +14 more
wiley   +1 more source